Ptc Therapeutics (PTCT) Debt to Equity (2016 - 2025)
Ptc Therapeutics (PTCT) has 14 years of Debt to Equity data on record, last reported at -$1.4 in Q4 2025.
- For Q4 2025, Debt to Equity fell 182.2% year-over-year to -$1.4; the TTM value through Dec 2025 reached -$1.4, down 182.2%, while the annual FY2025 figure was -$1.4, 182.2% down from the prior year.
- Debt to Equity reached -$1.4 in Q4 2025 per PTCT's latest filing, up from -$1.84 in the prior quarter.
- Across five years, Debt to Equity topped out at $237.26 in Q4 2021 and bottomed at -$3.89 in Q1 2022.
- Average Debt to Equity over 5 years is $10.98, with a median of -$1.09 recorded in 2023.
- Peak YoY movement for Debt to Equity: skyrocketed 34535.93% in 2021, then crashed 402.23% in 2025.
- A 5-year view of Debt to Equity shows it stood at $237.26 in 2021, then crashed by 100.78% to -$1.86 in 2022, then skyrocketed by 68.49% to -$0.58 in 2023, then increased by 15.38% to -$0.49 in 2024, then plummeted by 182.2% to -$1.4 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were -$1.4 in Q4 2025, -$1.84 in Q3 2025, and -$2.65 in Q2 2025.